Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

BD Alexander, OA Cornely, PG Pappas, R Miller, M Johnson, J Vazquez,  L Ostrosky-Zeichner, A Spec, R Rautemaa-Richardson, R Krause, GR Thompson, TJ Walsh, CG Morse, JW Sanders, D Andes, GM Lyon, FM Marty, MH Miceli,  TF Patterson, M Hoenigl, N Azie, DA Angulo
ID Week
October 2020

Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including Isolates with Elevated MIC’s to Echinocandins

Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

Oral Ibrexafungerp: An Investigational Agent for the Treatment of Acute and Recurrent Vulvovaginal Candidiasis

In Vitro Activity of Ibrexafungerp against 187 Fluconazole-susceptible and -resistant Candida Species Isolates from Patients with Vaginal Yeast Infections

Oral Ibrexafungerp Efficacy and Safety in the Treatment of Vulvovaginal Candidiasis: A Phase 3, Randomized, Blinded, study vs. Placebo (VANISH-303)

Jane Schwebke, MD
IDSOG Virtual Conference 2020

In Vitro Activity of Ibrexafungerp in pH 7.0 and pH 4.5 Testing Environments Against 187 Fluconazole-susceptible and -resistant Candida Species from Vulvovaginal Candidiasis Patients

Jack D. Sobel, MD
IDSOG Virtual Conference 2020

Current Challenges and Advancements in the Treatment of Vulvovaginal Candidiasis

Jack D. Sobel, MD
IDSOG Virtual Conference 2020

Ibrexafungerp in Combination with Azoles Against Clinical Isolates of Aspergillus, Including Those Resistant to Azoles

Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi